The American Cancer Society has revised its colorectal cancer screening guidance, shifting from a one-size-fits-all approach to a menu of accessible options aimed at catching more cancers earlier. The update keeps routine screening for average-risk adults starting at 45 and running through 75, while adding noninvasive tests to reach people who might skip a colonoscopy. New recommendations reflect both advances in detection technology and a public health push to lower barriers to testing.
The headline change is straightforward: screening still begins at 45 for most adults and continues through age 75 for those with more than a decade of life expectancy. Colonoscopy remains a key tool, but it’s no longer the only acceptable route. The society now endorses blood-based tumor DNA tests performed in the clinician’s office and stool-based at-home options that look for hidden blood and molecular markers.
Those new noninvasive choices are meant to increase participation by giving people realistic alternatives to an invasive procedure. A blood draw in a doctor’s office or a stool kit handled at home removes logistics and anxiety for many. That flexibility is being promoted as a way to close the gap between who should be screened and who actually gets tested.
Experts behind the guidance stress prevention as the priority. The report calls colorectal cancer a “highly preventable disease as much as a treatable one.” Offering multiple screening options, they argue, will help catch cancers earlier and reduce deaths by increasing the number of people who take part in testing.
“By offering more screening tools in our guideline update, more eligible adults will be able to participate in lifesaving colorectal cancer testing, helping to close the screening gap and catch more cancers at an earlier, treatable stage,” the report notes. That line gets to the heart of the update: more routes to detection equals more lives saved. Clinicians are being encouraged to present choices and follow up to ensure completion of whatever test patients pick.
The society also spelled out who might need different timing. People at higher risk because of family history, certain medical conditions, or prior polyps may need to start screening before 45 or be screened more frequently. At the other end of the spectrum, screening is discouraged for those older than 85, where harms can outweigh benefits.
Data cited by the society underline why this matters now. Early-stage colorectal cancer detected in the U.S. carries a five-year survival rate above 90 percent, so catching disease early pays off. Yet about one in three adults who should be screened have not been, and cases among younger adults have been rising.
A recent uptick in younger-onset diagnoses has researchers searching for causes, and nobody claims a single smoking gun. Experts say the trend looks like “an interplay of a person’s risk factors, overall makeup and early exposures.” “[Those] include dietary exposures, environmental exposures and possible antibiotic exposures, as well as lifestyle factors in the right host,” the statement explains, naming diet and environment among likely contributors.
Other research highlights lifetime heavy drinking as a possible risk factor, and well-known culprits remain significant: obesity, smoking, diets high in red and processed meats, inflammatory bowel disease, and family histories of polyps or cancer. Physicians are urged to take a detailed history and tailor screening recommendations accordingly.
Symptoms can be subtle or absent early on, which is why screening matters for people without complaints. Changes in “bowel habits” are the most reliable red flag, experts say, and other warning signs include fatigue from anemia, abdominal discomfort, rectal bleeding, weakness, and unexplained weight loss. When those signs appear, clinicians should act quickly to evaluate.
Practical messaging from the society boils down to a single point: the best test is the one that gets done. “no matter which test you choose, what’s most important is to get screened, and that includes underserved, rural and minority populations.” Providers should focus on removing barriers and ensuring follow-up so screening leads to diagnosis and treatment when needed.
